Dendreon to offer end-to-end cell therapy manufacturing

By The Science Advisory Board staff writers

California-based Dendreon Pharmaceuticals announced that it will offer end-to-end manufacturing for complex cell therapies.

The company is one of only four firms that manufacture cell therapies for commercial use in the U.S. In early 2021, Dendreon started to dedicate capacity for later-stage partner programs within its current infrastructure.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?